Geranylgeranyl diphosphate

DB07841

small molecule experimental

Deskripsi

Struktur Molekul 2D

Berat 450.449
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

431 Data
Leuprolide The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Goserelin.
Erythromycin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Azithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Moxifloxacin.
Ranolazine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Ranolazine.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Sulfisoxazole.
Amitriptyline The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Amitriptyline.
Methadone The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Methadone.
Diltiazem The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Diltiazem.
Clozapine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Sulpiride.
Nimodipine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Nimodipine.
Promazine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Promazine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Prochlorperazine.
Droperidol The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Droperidol.
Imipramine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Imipramine.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Chlorpromazine.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Geranylgeranyl diphosphate.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Ciprofloxacin.
Fluorouracil The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Fluorouracil.
Perflutren The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Perflutren.
Cinnarizine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Cinnarizine.
Atropine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Atropine.
Chloroquine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Chloroquine.
Efavirenz The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Efavirenz.
Adenosine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Adenosine.
Pentamidine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Pentamidine.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Gadobenic acid.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Carbinoxamine.
Dolasetron The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Dolasetron.
Roxithromycin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Roxithromycin.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Nalidixic acid.
Cinoxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Cinoxacin.
Loperamide The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Loperamide.
Granisetron The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Granisetron.
Ondansetron The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Ondansetron.
Levosimendan The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Levosimendan.
Mesoridazine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Mesoridazine.
Desloratadine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Desloratadine.
Telithromycin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Telithromycin.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Lomefloxacin.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Dimenhydrinate.
Primaquine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Primaquine.
Papaverine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Papaverine.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Chlorpheniramine.
Nifedipine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Nifedipine.
Levofloxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Levofloxacin.
Gemifloxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Gemifloxacin.
Ofloxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Ofloxacin.
Propafenone The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Propafenone.
Flecainide The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Flecainide.
Clarithromycin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Clarithromycin.
Levacetylmethadol The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Levacetylmethadol.
Saquinavir The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Saquinavir.
Clomipramine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Clomipramine.
Mibefradil The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Mibefradil.
Probucol The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Probucol.
Aceprometazine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Aceprometazine.
Terlipressin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Terlipressin.
Prenylamine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Prenylamine.
Fluspirilene The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Fluspirilene.
Lofexidine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Lofexidine.
Azimilide The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Azimilide.
Pracinostat The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Pracinostat.
Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Technetium Tc-99m ciprofloxacin.
Garenoxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Garenoxacin.
Tedisamil The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Tedisamil.
Tucidinostat The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Tucidinostat.
Telavancin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Telavancin.
Pazopanib The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Pazopanib.
Nemonoxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Nemonoxacin.
Panobinostat The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Panobinostat.
Nilvadipine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Nilvadipine.
Antazoline The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Antazoline.
Crizotinib The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Crizotinib.
Bedaquiline The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Bedaquiline.
Fendiline The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Fendiline.
Eperisone The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Eperisone.
Butriptyline The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Butriptyline.
Ceritinib The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Ceritinib.
Lenvatinib The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Lenvatinib.
Melperone The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Melperone.
Benidipine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Benidipine.
Dexchlorpheniramine maleate The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Dexchlorpheniramine maleate.
Amifampridine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Amifampridine.
Mocetinostat The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Mocetinostat.
Entinostat The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Entinostat.
Gilteritinib The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Gilteritinib.
CUDC-101 The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with CUDC-101.
Simendan The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Simendan.
Ricolinostat The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Ricolinostat.
Mizolastine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Mizolastine.
Abexinostat The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Abexinostat.
Oxatomide The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Oxatomide.
Sitafloxacin The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Sitafloxacin.
Sultopride The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Sultopride.
Otilonium The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Otilonium.
Nizofenone The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Nizofenone.
Bunaftine The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Bunaftine.

Target Protein

Farnesyl pyrophosphate synthase FDPS
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha FNTA
Protein farnesyltransferase subunit beta FNTB
Geranylgeranyl transferase type-1 subunit beta PGGT1B
Geranylgeranyl pyrophosphate synthase GGPS1
Geranylgeranyl transferase type-2 subunit alpha RABGGTA
Geranylgeranyl transferase type-2 subunit beta RABGGTB

Referensi & Sumber

Synthesis reference: Chikara Ohto, Chika Asada, Shinichi Ohnuma, Tokuzo Nishino, Kazutake Hirooka, Hisashi Hemmi, "Process for the production of prenyl diphosphate using mutants of geranylgeranyl diphosphate synthase." U.S. Patent US5885810, issued September, 1995.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul